Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The cityās leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,248
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
for
Urinary Bladder Neoplasms, Neoplasm Metastasis,
Location: Nashville TN, Atlanta GA, Cincinnati OH,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT05614739
Phase1, Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
for
Advanced HR+/HER2- Breast Cancer,
Location: Nashville TN, Atlanta GA, San Antonio TX
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07288359
Phase1, Phase2, Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
for
Prostatic Neoplasms
Location: Nashville TN, Atlanta GA, Charlotte NC, Houston TX,
Sponsor: Janssen Research & Development, LLC
Sex: Male
Age: 18+
Code: NCT06095089
Phase1, Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
for
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation,
Location: Nashville TN, Spartanburg SC, Chicago IL, Durham NC,
Sponsor: Institut de Recherches Internationales Servier
Sex: All
Age: 18+
Code: NCT06501625
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
for
Colorectal Neoplasms
Location: Nashville TN, Chattanooga TN, Atlanta GA, Jonesboro AR,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06750094
Phase3, Recruiting
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Nashville TN, Madison WI, Dallas TX, Toronto,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05007782
Phase1, Recruiting
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Location: Nashville TN, Hendersonville TN, Franklin TN, Smyrna TN,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07421700
Phase1, Phase2, Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Nashville TN, Atlanta GA, O'Fallon IL, Waukee IA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07266441
Phase2, Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
for
Solid Tumours, Melanoma
Location: Nashville TN, Louisville KY
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07224425
Phase1, Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
for
Hepatocellular Carcinoma (HCC)
Location: Nashville TN, Hackensack NJ, Portland OR
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07291076
Phase1, Phase2, Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
for
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR),
Location: Nashville TN, Indianapolis IN, Zion IL, Irving TX,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07403721
Phase1, Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma,
Location: Nashville TN, Atlanta GA, Columbia MO, Salem VA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07221149
Phase2, Phase3, Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
for
Squamous Non-small Cell Lung Cancer
Location: Nashville TN, St Louis MO, Ann Arbor MI, Cleveland OH,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07221474
Phase2, Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
for
Locally Advanced or Metastatic Malignant Solid Tumors
Location: Nashville TN, Fairfax VA, Hackensack NJ,